Advanced Therapies Europe is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market. By bringing these two groups together, new partnerships can be forged to solidify Europe as a hub for cell and gene therapy.
Presentations & Posters
CASE STUDY: SCALABLE PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS
Wednesday September 1, 2022 at 14:00 GMT
Strategic Technology Partnership Leader – Cell & Gene Therapy, Pall Corporation
Manufacturing for Commercialization
With continued clinical success and increased investment, gene therapy companies are looking toward manufacturing and commercialization of their lead therapies. The majority of gene therapies in clinical trials (92%) utilize viral vectors to carry the therapeutic gene into the target cells2. The most common method of making virus involves transfecting mammalian cells with one or more plasmid DNA to generate the viral vector. Once produced and harvested, the vector is then clarified, concentrated, purified, sterile filtered, quality tested, and stored for use either ex vivo or in vivo depending on the therapy and the virus type being used. Read More…